Quarterly report pursuant to Section 13 or 15(d)


EXCHANGEABLE NOTES AND CONVERTIBLE DEBENTURES (Details Narrative) - 7% Exchangeable Promissory Notes [Member] - USD ($)
1 Months Ended 2 Months Ended 6 Months Ended 12 Months Ended
May 06, 2021
Mar. 31, 2021
Nov. 30, 2020
Sep. 30, 2020
Jun. 30, 2021
Dec. 31, 2020
Aug. 31, 2020
Debt instrument principal amount       $ 375,000     $ 375,000
Exchangeable promissory note description     by reason of the Share Exchange, the four 7% Exchangeable Promissory Notes were automatically exchanged for 7% Convertible Debentures issued by Healthtech Solutions in a principal amount of $381,505, which was equal to the principal of and accrued interest on the Notes. Then, during December of 2020, Healthtech Solutions issued four additional 7% Convertible Debentures in the aggregate principal amount of $250,000 in exchange for payment of cash in that amount. On February 4, 2021 an additional debenture was issued in the amount $50,000. ,Medi-Scan issued four 7% Exchangeable Promissory Notes in the aggregate principal amount of $375,000. Principal and interest were payable on the Notes on January 31, 2021      
Common Shares [Member]              
Convertible debenture conversion term   The 7% Convertible Debentures were convertible into common stock, at the holders’ option, at a 30% discount to the market price of the Company’s common stock. The Company determined that the conversion feature represented a derivative financial instrument embedded in the Debentures. The accounting treatment of derivative financial instruments requires that the Company record the fair value of that derivative financial instrument as a discount to the value of the Debentures as of the inception date of each Debenture.          
Fair value of derivative liability   $ 349,202          
Amortized Interest expense         $ 27,303    
Interest expenses         $ 351,202 $ 9,277  
Debt instrument Unamortized discount           $ 325,824  
Common stock shares issued upon debt conversion 3,507,164